Effects of ischaemia and reperfusion on vasoactive neuropeptide levels in the canine infrarenal aortic revascularization model

Vascular

Volumn 4, Issue 4, 1996, Pages 470-475

  Dovgan, P S ^a   Edwards, J D ^a   Rowley, J M ^a   Agrawal, D K ^a   Adrian, T E ^a,b  

^a Creighton Diabetes Center   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hind limb ischaemia; infrarenal aortic revascularization; vasoactive neuropeptide levels

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; ENDOTHELIN 1; NEUROPEPTIDE; NEUROPEPTIDE Y; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL MODEL; AORTA CLAMPING; AORTA RECONSTRUCTION; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DOG; FEMALE; LIMB ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; REVASCULARIZATION;

EID: 0030208610     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: 10.1177/096721099600400411     Document Type: Article

References (47)

1. Hermreck AS. Prevention and management of surgical complies-tions during repair of abdominal aortic aneurysms. Surg Clin North Am. 1989; 69: 869–894.
2. Gelman S, Patel K, Bishop SP, et al Renal and splanchnic circulation during infrarenal aortic crossclamping. Arch Surg 1984; 119: 1394–1399.
3. Abbott WM, Cooper JD, Austen WG. The effect of aortic-clamping and declamping on renal blood flow distribution. J Surg Res 1973; 14: 385–392.
4. Frank RS, Moursi MM, Podrazik RM, et al Renal vasoconstriction and transient declamp hypotension after infrarenal aortic occlusion: role of plasma purine degradation products. J Vasc Surg 1988; 7: 515–523.
5. Pull Ter Gunne AJ, Bruining HA, Obertop H. Haemodynamics of “optimal” hydration in aortic cross-clamping. Netherlands J Surg 1990; 42: 113–117.
6. Colson P, Capdevilla X, Cuchet D, et al Does choice of the anesthetic influence renal function during infrarenal aortic surgery? Anesth Analg 1992; 74: 481–485.
7. Takahashi K, Ghatei MA, Lam H-C, et al Elevated plasma endothelin in diabetes mellitus. Diahetologia 1990; 33: 306–310.
8. Long RG, Bryant MG. Vasoactive intestinal polypeptide. In: Bloom SR, Long RG,eds. Radioimmunoassay of Gut Regulatory Peptides. Philadelphia: Saunders, 1982: 120–130.
9. Yamashita Y, Kako N, Homma K, et al Neuropeptide release from the isolated, perfused, lower esophageal sphincter region of the rabbit and the effects of vasoactive intestinal polypeptide on the sphincter. Surgery 1992; 112: 227–234.
10. Allen JM, Yeats JC, Adrian TE, et al Radioimmunoassay of neuropeptide Y. Regul Pept 1984; 8: 61–70.
11. Wallenstein S, Zucker CL, Fleiss JI. Some Statistical methods useful in circulation research. Circulation Res 1980; 47: S1–10.
12. Yanagisawa M, Kuihara H, Kimera S, et al A novel potent vasoconstrictor polypeptide produced by vascular endothelial cells. Nature 1988; 332: 411–415.
13. Chester AH, O'Neil GS, Allen SP, et al Effect of endothelin on normal and diseased coronary arteries. Eur J Clin Invest 1992; 22: 210–213.
14. Anggard F, Botting R, and Vane J. Kndothelins. Blood Vessels 1990; 27: 269–281.
15. Watanabe T, Susuki N, Shimamoto N, et al Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ-Res 1991; 69: 370–377.
16. Edwards JD, Dovgan PS, Rowley JM, et al Endothelin-1 levels in ischaemia, reperfusion, and haemorrhagic shock in the canine infrarenal aortic revascularization model. Euro J Vasc Surg 1994; 8: 729–734.
17. Watanabe T, Suzuki N, Shimamoto N, et al Endothelin in myocardial infarction. Nature 1990; 344: 1145.
18. Walder CE, Thomas GR, Thiemermann C, et al The haemodynamic effects of endothelin-1 in the pithed rat. J Cardiovasc Pharm 1989; 13(suppl 5): S93–7.
19. Pernow J, Franco-Cereceda A, Matran R, et al Effect of endothelin-1 on regional vascular resistances in the pig. J Cardiovasc Pharm 1989; 13(suppl 5): S205–6.
20. Stingo AJ, Clavell AL, Aarhus LL, et al Biological role of the endothelin-A receptor in aortic cross-clamping. Hypertension 1993; 22: 62–66.
21. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc Natl Acad Sci USA 1982; 79: S485–9.
22. Lundberg JM, Terenius L, Hokfelt T, et al Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand 1982; 116: 477–480.
23. Ekblad E, Edvinsson C, Wahlestedt R, et al Neuropeptide Y (NPY) co-exists and co-operates with norepinephrine in perivascular nerve fibers. Regul Pept 1984; 8: 225–235.
24. Franco-Cereceda A, Lundberg JM, Dahlof C. Neuropeptide Y and sympathetic control of heart contractility and coronary vascular tone. Acta Physiol Scand 1985; 124: 361–369.
25. Franco-Cereceda A, Owall A, Settergren G, et al Release of neuropeptide Y and norepinephrine from the human heart after aortic occlusion during coronary artery surgery. Cardiovasc Res 1990; 24: 242–246.
26. Maturi MF, Greene R, Speir E, et al Neuropeptide Y: a peptide found in human coronary arteries constricts primarily small coronary arteries to produce myocardial ischaemia in dogs. J Clin Invest 1989; 83: 1217–1224.
27. Echtenkamp SF, Dandridge PK Renal actions of neuropeptide Y in the primate. Am J Physiol 1989; 256: F524–31.
28. Komaru T, Ashikawa K, Kanatsuka H, et al Neuropeptide Y modulates vasoconstriction in coronary microvessels in the beating canine heart. Circ Res 1990; 67: 1142–1151.
29. Han C, Abel PW, Neuropeptide Y potentiates contraction and inhibits relaxation of rabbit coronary arteries. J Cardiovasc Pharmacol 1987; 9: 675–681.
30. Persson PB, Ehmke H, Nafz B, et al Effects of neuropeptide-Y on renal function and its interaction with sympathetic stimulation in conscious dogs. J Physiol (Lond) 1991; 444: 289–302.
31. Nobiling R, Gabel M, Persson PB, et al Differential effect of neuropeptide-Y on membrane potential of cells in renal arterioles of the hydronephrotic mouse J Physiol (Lond) 1991; 444: 317–327.
32. Macho P, Perez R, Huidobro-Toro JP, et al Neuropeptide Y (NPY): a coronary vasoconstrictor and potentiator of cate-cholamine-induced coronary constriction. Eur J Pharmacol 1989; 167: 67–74.
33. Yang ZH, Richard V, von Segesser L, et al Threshold concentrations of endothelin-1 potentiate contractions of norepinephrine and serotonin in human arteries: a new mechanism of vasospasm? Circulation 1990; 82: 188–195.
34. Pearse AGE. Peptides in brain and intestine. Nature 1976; 262–92–4.
35. Said SI. Vasoactive intestinal polypeptide (VIP) as a neural peptide. In; Miyouki A, Grossman M, eds. Gut Peptides, Secretion, function and Clinical Aspects. Amsterdam: Elsevier North Holland Biomedical Press, 1979: 268–273.
36. Bryant MG, Polak JM, Modlin I, et al Possible dual role for vasoactive intestinal peptide as gastrointestinal hormone and neurotransmitter substance. Lancet 1976; 1: 991–993.
37. Frase LL, Gaffney FA, Lane LD, et al Cardiovascular effects of vasoactive intestinal peptide in healthy subjects. Am J Cardiol 1987; 60: 1356–1361.
38. Gaumann DM, Yaksh TL. Adrenal and intestinal secretion of catecholamines and neuropeptides during splanchnic artery occlusion shock. Circulatory Shock 1988; 26: 391–407.
39. Somjen G, Fletcher DR, Shulkes A, et al Effect of vasoactive intestinal polypeptide on systemic and splanchnic haemodynamics: role in vasodilation following mesenteric ischaemia Digestion 1988; 40: 133–143.
40. Modlin LM, Bloom SR, Mitchell S. Plasma vasoactive intestinal polypeptide(VIP) levels and intestinal ischaemia. Experientia 1978; 34: 535–536.
41. Mulderry PK, Ghatei MA, Rodrigo J, et al Calcitonin gene-related peptide in cardiovascular tissues of the rat. Neuroscience 1985; 14: 947–954.
42. Skofitsch G, Jacobowitz DM. Calcitonin gene-related peptide: detailed immunohistochemical distribution in the central nervous system. Peptides 1985; 6: 721–745.
43. Gardiner SM, Compton AM, Kemp PA, et al Haemodynamic effect of human a-calcitonin gene-related peptide following administration of endothelin-1 or NG-nitro-L-argine methyl ester in conscious rats. Br J Pharmacol 1991; 103: 1256–1262.
44. Gardiner SM, Compton AM, Bennett T. Regional haemodynamic effects of calcitonin gene-related peptide. Am J Physiol 1989; 256 R332–8.
45. Li JZ, Wang HY, Tang J, et al The effect of calcitonin-gene-related peptide on acute ischemia-reperfusion renal injury: Ultrastrucrural and membrane lipid-peroxidation studies Ren Fail 1992; 14: 11–16.
46. Edwards JD, Dovgan PS, Rowley JM, et al Neuropeptide Y levels in ischaemia and reperfusion in the canine infrarenal aortic revascularization model. Ann Vasc Surgery 1994; 8: 350–355.
47. Rosa RM, Silva P, Stoff JS, et al Effect of vasoactive intestinal peptide on isolated perfused rat kidney. Am J Physiol 1985; 249: E494–7.